NCT02113020

A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects

A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Takeda · Industry
• Sex: Female
• Age: 20 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The objective of this clinical trial is to examine the clinical pharmacology properties of TAK-233 in healthy female subjects

Detailed description

The primary objective of this study is to examine the pharmacodynamics and the safety of TAK-233 administered as a single dose in healthy women.

Conditions

• Clinical Pharmacology

Interventions

Type	Name	Description
DRUG	TAK-233	Oral administration of TAK-233
DRUG	Placebo	Oral admininstration of Placebo

Timeline

• Start date: 2014-02-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2014-04-14
• Last updated: 2014-10-21

Locations

1 site across 1 country: Japan